MetaCap

Maravai LifeSciences (MRVI) vs Vera Therapeutics (VERA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Maravai LifeSciences (MRVI) has outperformed Vera Therapeutics (VERA) over the past year, gaining 86.1% versus a loss of 10.6%. Over five years, VERA leads with a -15.2% price change compared with -83.2% for MRVI. Vera Therapeutics is the larger company by market cap ($1.84 billion vs $1.81 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MRVI+86.13%VERA-10.58%
+148%+58%-33%
Nov 21, 20251 yearNov 20, 2026
MRVI-81.37%VERA-18.43%
+80%-12%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MRVI versus VERA key metrics
MetricMRVIVERA
Share price$6.98$25.45
Market cap$1.81B$1.84B
1-day change-2.92%-4.86%
YTD return+114.77%-49.74%
1-year return+86.13%-10.58%
5-year return-83.18%-15.17%
EPS (TTM)$-0.44$-5.90
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$185.74M—
Revenue growth (YoY)-28.34%—
Net income (latest FY)$-130.77M$-299.62M
Gross margin18.30%—
Operating margin-115.89%—
Net margin-70.41%—
52-week high$9.42$56.05
52-week low$2.80$25.08
Distance from 52-week high-25.90%-54.59%
Analyst consensusbuystrong_buy
Avg. price target upside+38.11%+180.39%
Average volume2.72M1.95M
Shares outstanding149.25M72.30M
Employees410362
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MRVI has outperformed VERA by 96.7 percentage points over the past year.

About Maravai LifeSciences

MRVI stock →

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.

Health Care · Biotechnology: Pharmaceutical Preparations · 410 employees

About Vera Therapeutics

VERA stock →

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 362 employees

MRVI vs VERA FAQ

Which is bigger, Maravai LifeSciences or Vera Therapeutics?

Vera Therapeutics (VERA) is larger, with a market capitalization of $1.84B compared with $1.81B for Maravai LifeSciences (MRVI).

Which stock has performed better over the past year, MRVI or VERA?

MRVI returned +86.13% over the past 12 months, compared with -10.58% for VERA (price return, excluding dividends). Past performance does not predict future results.

Are Maravai LifeSciences and Vera Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons